
The Single-Prescription Solution: Inside the Science of PILLXCHRZE
By leveraging programmable peptide-RNA complexes, the Global Synthetic Biology Consortium's new oral therapeutic selectively dismantles malignant tumors in under a month without harming healthy tissue. This milestone signals the end of toxic treatments and turns a highly feared disease into a swiftly managed, single-prescription condition.
Read full report →










































